These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38409114)

  • 1. Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease.
    Hollenback D; Hambruch E; Fink G; Birkel M; Schulz A; Hornberger M; Liu K; Staiger KM; Krol HD; Deuschle U; Steeneck C; Kinzel O; Liles JT; Budas G; Watkins WJ; Kremoser C
    J Pharmacol Exp Ther; 2024 Feb; ():. PubMed ID: 38409114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
    Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
    JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.
    Schwabl P; Hambruch E; Budas GR; Supper P; Burnet M; Liles JT; Birkel M; Brusilovskaya K; Königshofer P; Peck-Radosavljevic M; Watkins WJ; Trauner M; Breckenridge DG; Kremoser C; Reiberger T
    Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33435509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers.
    Younis IR; Kirby BJ; Billin AN; Xiao D; Song Q; Watkins TR; Othman AA
    Clin Transl Sci; 2023 Mar; 16(3):536-547. PubMed ID: 36573450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
    Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor.
    Jiang L; Liu X; Wei H; Dai S; Qu L; Chen X; Guo M; Chen Y
    Biochem Biophys Res Commun; 2022 Mar; 595():1-6. PubMed ID: 35091108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease.
    Fiorucci S; Biagioli M; Baldoni M; Ricci P; Sepe V; Zampella A; Distrutti E
    Expert Opin Drug Discov; 2021 Oct; 16(10):1193-1208. PubMed ID: 33849361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.
    Zhang T; Feng S; Li J; Wu Z; Deng Q; Yang W; Li J; Pan G
    Arch Toxicol; 2022 Jun; 96(6):1829-1843. PubMed ID: 35267068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
    Patel K; Harrison SA; Elkhashab M; Trotter JF; Herring R; Rojter SE; Kayali Z; Wong VW; Greenbloom S; Jayakumar S; Shiffman ML; Freilich B; Lawitz EJ; Gane EJ; Harting E; Xu J; Billin AN; Chung C; Djedjos CS; Subramanian GM; Myers RP; Middleton MS; Rinella M; Noureddin M
    Hepatology; 2020 Jul; 72(1):58-71. PubMed ID: 32115759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
    Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
    Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
    J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
    J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
    Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
    Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease.
    Traussnigg S; Halilbasic E; Hofer H; Munda P; Stojakovic T; Fauler G; Kashofer K; Krssak M; Wolzt M; Trauner M
    Wien Klin Wochenschr; 2021 May; 133(9-10):441-451. PubMed ID: 32930860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FXR agonists in NASH treatment.
    Adorini L; Trauner M
    J Hepatol; 2023 Nov; 79(5):1317-1331. PubMed ID: 37562746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance.
    Ma Y; Huang Y; Yan L; Gao M; Liu D
    Pharm Res; 2013 May; 30(5):1447-57. PubMed ID: 23371517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
    Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
    Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal FXR Ligands: Current Status and Clinical Applications.
    Gege C; Hambruch E; Hambruch N; Kinzel O; Kremoser C
    Handb Exp Pharmacol; 2019; 256():167-205. PubMed ID: 31197565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.